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Background: Gastric cancer is the second leading cause of cancer death and remains a major clinical challenge
due to poor prognosis and limited treatment options. Long noncoding RNAs (lncRNAs) have emerged recently as
major players in tumor biology and may be used for cancer diagnosis, prognosis, and potential therapeutic targets.
Although downregulation of lncRNA GAS5 (Growth Arrest-Specific Transcript) in several cancers has been studied,
its role in gastric cancer remains unknown. Our studies were designed to investigate the expression, biological role
and clinical significance of GAS5 in gastric cancer.
Methods: Expression of GAS5 was analyzed in 89 gastric cancer tissues and five gastric cancer cell lines by
quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Over-expression and RNA interference
(RNAi) approaches were used to investigate the biological functions of GAS5. The effect of GAS5 on proliferation
was evaluated by MTT and colony formation assays, and cell apoptosis was evaluated by hochest stainning. Gastric
cancer cells transfected with pCDNA3.1 -GAS5 were injected into nude mice to study the effect of GAS5 on
tumorigenesis in vivo. Protein levels of GAS5 targets were determined by western blot analysis. Differences
between groups were tested for significance using Student’s t-test (two-tailed).
Results: We found that GAS5 expression was markedly downregulated in gastric cancer tissues, and associated with
larger tumor size and advanced pathologic stage. Patients with low GAS5 expression level had poorer disease-free
survival (DFS; P = 0.001) and overall survival (OS; P < 0.001) than those with high GAS5 expression. Further multivariable
Cox regression analysis suggested that decreased GAS5 was an independent prognostic indicator for this disease
(P = 0.006, HR = 0.412; 95%CI = 2.218–0.766). Moreover, ectopic expression of GAS5 was demonstrated to decrease
gastric cancer cell proliferation and induce apoptosis in vitro and in vivo, while downregulation of endogenous
GAS5 could promote cell proliferation. Finally, we found that GAS5 could influence gastric cancer cells proliferation,
partly via regulating E2F1 and P21 expression.
Conclusion: Our study presents that GAS5 is significantly downregulated in gastric cancer tissues and may
represent a new marker of poor prognosis and a potential therapeutic target for gastric cancer intervention.
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Gastric cancer is the second leading cause of cancer
death, and is the most common gastrointestinal malig-
nancy in East Asia, Eastern Europe, and parts of Central
and South America [1]. Although the majority of the
patients at an early stage of gastric carcinoma can be
cured by surgery, more than half of those at an advanced
stage of the disease die of carcinoma recurrence, even
after undergoing curative gastrectomy [2]. Therefore,
better understanding of the pathogenesis and identification
of the molecular alterations is essential for the development
of useful indicators that aid novel effective therapies for
gastric cancer [3-5].
It is well known that protein-coding genes account for
only 2% of the total genome, whereas the vast majority
of the human genome can be transcripted into noncod-
ing RNAs [6-9]. Among them are long noncoding RNAs
(lncRNAs), which are more than 200 nt in length with
limited or no protein-coding capacity. LncRNAs are
often expressed in a disease-, tissue- or developmental
stage-specific manner making these molecules attract-
ive therapeutic targets and pointing toward specific
functions for lncRNAs in development and diseases, in
particular human cancer [10-13]. Multiple lines of evidence
have revealed the contribution of lncRNAs as having
oncogenic and tumor suppressor roles in tumorigen-
esis. A famous oncogenic lncRNA involved in tumor
pathogenesis is known as HOTAIR (Hox transcript
antisense intergenic RNA), which has been consistently
upregulated and identified as a strong prognosis marker of
patient outcomes such as metastasis and patient survival
in diverse human cancers. The studies also revealed that
HOTAIR exerts its oncogenic functions via binding the
PRC2 (polycomb repressive complex 2), which methylates
histone H3 on K27 to promote gene repression [14-16]. A
similar mode of action is executed by the lncRNA ANRIL
(antisense non-coding RNA in the INK4 locus), a novel
tumor suppressor interacting with the PRC2 complex
to block the activity of p15INK4B, a well-known tumor
suppressor gene. Moreover, the depletion of ANRIL in-
creases the expression of p15INK4B and inhibits cellular
proliferation tumorigenesis [17]. Maternally expressed
gene 3 (meg3) also represents a tumor suppressor gene
that encodes a MEG3 lncRNA, which expression is lost
in an expanding list of primary human tumors, and re-
expression of MEG3 could induce cell growth arrest and
promote cell apoptosis partly via the activation of P53
[18]. Nevertheless, the overall pathophysiological contri-
butions of lncRNAs to gastric cancer remain largely
unknown.
In our current study, which seeks to determine the
clinical significance and functions of dysregulated lncRNAs
in gastric carcinogenesis, we investigated lncRNA GAS5
(Growth Arrest-Specific Transcript 5), which was previouslyshown to be consistently downregulated and identified as
a tumor-suppressor lncRNA in prostate cancer cells, renal
cell carcinoma cells and breast cancer cells [19-21],
though its functional significance has not yet been estab-
lished. In this study, we demonstrated that decreased
GAS5 expression was a characteristic molecular change in
gastric cancer and investigated the effect of altered GAS5
level on the phenotypes of gastric cancer cells in vitro and
in vivo. Then, we analyzed the potential relationship be-
tween this lncRNA level in tumor tissues and existing
clinicopathological features of gastric cancer, as well as
clinical outcome. Our findings suggest that lncRNA GAS5
may represent a novel indicator of poor prognosis in
gastric cancer and may be a potential therapeutic target
for diagnosis and gene therapy.
Methods
Tissue collection
89 gastric cancer samples were obtained from patients
who had underwent surgery at Jiangsu province hospital
between 2006 and 2008, and were diagnosed with gastric
cancer (stages II, III, and IV; seventh edition of the AJCC
Cancer Staging Manual) based on histopathological evalu-
ation. Clinical pathology information was available for
all samples (Table 1). No local or systemic treatment
was conducted in these patients before the operation.
All specimens were immediately frozen in liquid nitrogen,
and stored at −80°C until RNA extraction. The study was
approved by the Research Ethics Committee of Nanjing
Medical University, China. Informed consents were ob-
tained from all patients.
Cell lines and culture conditions
Five gastric cancer cell lines (SGC7901, BGC823, MGC803,
MKN45, MKN28), and a normal gastric epithelium cell
line (GES-1) were purchased from the Institute of Bio-
chemistry and Cell Biology of the Chinese Academy of
Sciences (Shanghai, China). Cells were cultured in RPMI
1640 or DMEM (GIBCO-BRL) medium supplemented
with 10% fetal bovine serum (10% FBS), 100 U/ml penicil-
lin, and 100 mg/ml streptomycin in humidified air at 37°C
with 5% CO2.
RNA extraction and qRT-PCR analyses
Total RNA was extracted from tissues or cultured cells
using TRIzol reagent (Invitrogen, Carlsbad, CA). For
qRT-PCR, RNA was reverse transcribed to cDNA by
using a Reverse Transcription Kit (Takara, Dalian, China).
Real-time PCR analyses were performed with Power SYBR
Green (Takara, Dalian China). Results were normalized to
the expression of GAPDH. The PCR primers for GAS5 or
GAPDH were as follows: GAS5 sense, 5’- CTTCTGGGC
TCAAGTGATCCT-3’ and reverse, 5’- TTGTGCCATGA
GACTCC ATCAG-3’; GAPDH sense, 5’-GTCAACGGA
Table 1 Clinicopathological characteristics and GAS5
expression in 89 patient samples of gastric cancer
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TGGCAGTGAT-3’. qRT-PCR and data collection were
performed on ABI 7500. The relative expression of GAS5
was calculated and normalized using the 2−ΔΔCt method
relative to GAPDH.
Plasmid construct
To generate a GAS5 expression vector, the entire se-
quence of human GAS5 (NR_002578.2, 651 bp) was
synthesized and subcloned into pCDNA3.1 vector with
incorporate external NheI and BamHI sites, respectively
(Invitrogen, Shanghai, China).
Transfection of gastric cancer cells
All plasmid vectors (pCDNA3.1-GAS5 and empty vector)
for transfection were extracted by DNA Midiprep kit
(Qiagen, Hilden, Germany). Gastric cells cultured in
six-well plate were transfected with the pCDNA3.1-GAS5,
empty vector, si-GAS5 or si-NC using Lipofectamine2000
(Invitrogen, Shanghai, China) according to the manufac-
turer’s instructions. Cells were harvested after 48 hours
for qRT-PCR and western blot analyses. siRNAs for the
human GAS5 (1#: 5’-CUUGCCUGGACCAGCUUAA
UU-3’; 2#: CACCAUUUCAACUU CCAG CUUUCU
G;3#: UACCCAAGCAAGUCAUCCAUGGAUA) and the
negative control siRNA (5’-UUCUCCGAACGUGUCACG
UUU-3’) were purchased from Invitrogen (Invitrogen,
Carlsbad, CA).
Cell proliferation assays
A cell proliferation assay was performed with MTT kit
(Sigma, St. Louis, Mo) according to the manufacturer's
instruction. Viable cells were counted by trypan blue
staining. For the colony formation assay, cells were placed
into 6-well plate and maintained in media containing 10%
FBS for 2 weeks. Colonies were fixed with methanol and
stained with 0.1% crystal violet (Sigma, St. Louis, Mo).
Visible colonies were manually counted.
Hoechst staining assay
SGC-7901 and BGC-823 cells transfected with pCDNA3.1-
GAS5 or empty vector were cultured in six-well cell culture
plates, and Hoechst 33342 (Sigma, St Louis, MO, USA)
was added to the culture medium; changes in nuclear
morphology were detected by fluorescence microscopy
using a filter for Hoechst 33342 (365 nm). For quantifi-
cation of Hoechst 33342 staining, the percentage of
Hoechst-positive nuclei per optical field (at least 50 fields)
was counted.
Western blot assay and antibodies
Cells protein lysates were separated by 10% SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE), transferred
to 0.22 μm NC membranes (Sigma) and incubated with
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to visualize the bands and the intensity of the bands was
quantified by densitometry (Quantity One software; Bio-
Rad, CA, USA). GAPDH antibody was used as control,
Anti-E2F1, cyclinD1, P21 and cleaved caspase-3 (1:1000)
were purchased from Cell Signaling Technology, Inc
(CST).
Tumor formation assay in a nude mouse model
4 weeks female athymic BALB/c nude mice were
maintained under specific pathogen-free conditions and
manipulated according to protocols approved by the
Committee on the Ethics of Animal Experiments of the
Nanjing medical University. SCG7901 cells transfected
with pCDNA3.1-GAS5 or empty vector were harvested
from six-well cell culture plates, washed with PBS, and
resuspended at a concentration of 1 × 108 cells/mL. A
volume of 100 μL of suspended cells was subcutaneouslyFigure 1 Relative GAS5 expression in gastric cancer tissues and its cli
tissues (n = 89) in comparison with corresponding non-tumor normal tissue
to GAPDH expression. Data was presented as fold-change in tumor tissues re
while the blue as underexpression. (B) According to the median ratio of relati
into two groups: relative high-GAS5 group (n = 45, blue column) and relative
survival and overall survival curves according to GAS5 expression level.injected into a single side of the posterior flank of each
mouse. The subcutaneous growth of tumor was examined
every three days, and tumor volumes were calculated
using the equation V = 0.5 × D × d2 (V, volume; D, longitu-
dinal diameter; d, latitudinal diameter) [22]. At 18 days
post injection, the mice were sacrificed and tumor weights
were measured and also used for further analysis. This
study was carried out in strict accordance with the rec-
ommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
Statistical analysis
Statistical analysis was performed using the SPSS software
package (version 20.0, SPSS Inc). Statistical significance
was tested by a Student’s t-test or a Chi-square test as
appropriate. Survival analysis was performed using the
Kaplan-Meier method, and the log-rank test was used to
compare the differences between patient groups.nical significance. (A) Relative expression of GAS5 in gastric cancer
s (n = 89). GAS5 expression was examined by qRT-PCR and normalized
lative to normal tissues. The red column was defined as overexpression,
ve GAS5 expression (0.38) in tumor tissues, GAS5 expression was classified
low-GAS5 group (n = 44, red column). (C, D) Kaplan-Meier disease-free
Table 2 Correlation between GAS5 expression and
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Expression of GAS5 is downregulated in human gastric
cancer tissues
We firstly examined GAS5 expression level in 89 paired
gastric cancer samples and adjacent, histological normal
tissues by qRT-PCR, and normalized to GAPDH. Figure 1A
showed that the GAS5 level was significantly downregu-
lated in 89% (79/89) gastric cancer tissues compared with
corresponding adjacent non-tumorous tissues. In cancerous
tissues, GAS5 expression was at a level lower than that of
normal specimens, with the median ratio of 0.38 compared
with normal counterparts. These data indicate that ab-
normal GAS5 expression may be related to gastric cancer
pathogenesis.
The relationship between GAS5 expression and
clinicopathological factors in patients with gastric cancer
The clinical pathology findings of 89 gastric carcinoma
patients are shown in Table 1. According to the median
ratio of relative GAS5 expression (0.38) in tumor tissues,
the 89 gastric cancer patients were classified into two
groups: relative high-GAS5 group (n = 45, GAS5 expres-
sion ratio ≥median ratio) and relative low-GAS5 group
(n = 44, GAS5 expression ratio ≤median ratio) (Figure 1B).
Clinicopathologic factors were compared between the two
groups (Table 2). The low-GAS5 group was correlated
with larger tumor size (p = 0.008), higher TNM stage (P <
0.001), deeper depth of invasion (P < 0.001) and more re-
gional lymph nodes (P < 0.001) than the high-GAS5 group.
However, GAS5 expression level was not associated
with other parameters such as gender (P = 0.101), age
(P = 0.338), tumor location (P = 0.839), lymphatic metasta-
sis (P = 0.072), etc. (Table 2).
Association of GAS5 expression with patients’ survival
We further examined whether GAS5 expression level
correlated with outcome of gastric cancer patients after
gastrectomy. Disease-free survival (DFS) and overall sur-
vival (OS) curves were plotted according to GAS5 expres-
sion level by the Kaplan–Meier analysis and log-rank test,
respectively, and the results were presented in Figure 1C
and D. Remarkably, patients with low GAS5 expression
level had poorer disease-free survival (P = 0.001) and
overall survival (P < 0.001). With regard to OS, the overall
3-year accumulative survival rates of patients with high
GAS5 expression were 49%. For patients with low GAS5
expression, however, the rates were 30.9%. Low GAS5
expression indicated a shorter overall survival time of
patients (median OS: 13 months) compared with high
GAS5 expression (median OS: 31 months). Moreover,
3 years of disease-free survival for high GAS5 expression
was 33.7%, while was 29.8% for low GAS5 expression.
The median survival time for high GAS5 expression is
28 months, while is 11 months for low GAS5 expression.
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sion of GAS5 in gastric cancer was significantly correlated
with patients’ survival time.Deregulated expression of GAS5 is an independent
prognostic predictor for patient with gastric cancer
In order to estimate the clinical significance of various
prognostic factors that might influence survival in the
study population, univariate analyses was performed
for DFS or OS in 89 patients with gastric cancer, respect-
ively. As shown in Table 3, TNM stage, distant metastasis
and GAS5 expression were statistically significant risk
factors affecting DFS or OS of patients. The other clin-
icopathological features, such as age, gender, tumor
location, and tumor size were not statistically signifi-
cant prognosis factors (P > 0.05). Low intratumoral GAS5
expression is a significant negative predictor for DFS
(hazard ratio [HR], 0.407; 95% confidence interval [CI],
0.235 to 0.706; P = 0.001) or OS (HR, 0.591; 95% CI,
0.436 to 0.803; P = 0.001). To evaluate the robustness of
the prognostic value of intratumoral GAS5 expression,
variables with a value of P < 0.05 were selected for
multivariate analysis. As shown in Table 3, multivariate
analysis revealed that GAS5 expression and TNM stage
were independent prognostic markers for gastric cancer.
Taken together, these data indicate that low GAS5
expression level is an independent risk factor for gastric
cancer patients.Table 3 Univariate and multivariate Cox regression analyses G
Variables
Univariate analysis
Age (<50 years vs. >50 years)
Gender (male vs. female)
Location (Distal vs. Middle + Proximal)
tumor size (>5 cm vs. <5 cm)
Histologic differentiation (Well + Moderately vs. Poorly + Undifferentiated)
Invasion depth (T1 + T2 vs.T3 + T4)
TNM stage (I + II vs. III + IV)
Lymphatic metastasis (No vs. Yes)
Regional lymph nodes (PN0+ PN1vs. PN2+ PN3)
Distant metastasis (No vs. Yes)
Expression of GAS5 (High vs. Low)
Multivariate analysis
TNM stage (I + II vs. III + IV)
Distant metastasis (No vs. Yes)
Expression of GAS5 (High vs. Low)
DFS, disease-free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confideManipulation of GAS5 expression level in gastric cancer cells
To evaluate the biological functions of GAS5, we first
examined the expression of GAS5 in a variety of cell
lines, including SGC7901, BGC823, MGC803, MKN45,
MKN28, and normal gastric epithelium cell line GES-1,
by qRT-PCR. The results showed that GAS5 expres-
sion was obviously downregulated in gastric cancer cells
(Figure 2A), suggesting that a decrease in expression levels
may be significant in gastric carcinogenesis.
In order to manipulate GAS5 level in gastric cancer
cells, pCDNA3.1-GAS5 vector was transfected into
BGC823 and SGC7901 cells. Expression of GAS5 was
assessed using qRT-PCR analysis and a respective 159-fold
and 93-fold increase in the pCDNA3.1-GAS5-transfected
cells compared with the vector controls (Figure 2B).
Furthermore, GAS5 siRNAs was transfected into MGC803
cells to downregulate endogenous GAS5 expression,
qRT-PCR analysis revealed that GAS5 expression was
effectively knocked down in si-GAS5 transfected cells
when compared with si-NC control cells (Figure 2C).Effect of GAS5 on gastric cancer cell proliferation and
apoptosis in vitro
To assess the biological role of GAS5 in gastric cancer,
we investigated the effect of targeted knockdown or
overexpression of GAS5 on cell proliferation and apoptosis.
MTT assay and trypan blue staining revealed that cell
growth was significantly impaired in pCDNA3.1-GAS5AS5 for DFS or OS of patients in study cohort (n = 89)
DFS OS
HR 95% CI P value HR 95% CI P value
.
1.122 0.659-1.910 0.671 1.057 0.589-1.899 0.852
1.584 0.907-2.768 0.106 1.739 0.933-3.240 0.082
1.232 0.811-1.872 0.327 1.498 0.830-2.702 0.180
1.493 0.876-2.543 0.141 1.260 0.938-1.692 0.124
0.743 0.428-1.288 0.289 0.798 0.436-1.458 0.463
0.629 0.370-1.069 0.087 0.724 0.403-1.300 0.279
0.521 0.303-0.896 0.018** 0.433 0.239-0.786 0.006**
0.838 0.642-1.093 0.192 0.899 0.671-1.204 0.474
0.584 0.332-1.024 0.061 0.575 0.310-1.065 0.078
0.456 0.264-0.787 0.005** 0.432 0.231-0.811 0.009**
0.407 0.235-0.706 0.001** 0.591 0.436-0.803 0.001**
0.631 0.357-1.115 0.113 0.537 0.289-1.000 0.049*
0.384 0.123-1.197 0.099 0.381 0.105-1.389 0.144
0.466 0.263-0.828 0.009** 0.412 0.218-0.776 0.006**
nce interval. *P < 0.05 and **P < 0.01.
Figure 2 The level of GAS5 expression in gastric cancer cells. (A) Results from qRT-PCR demonstrating GAS5 expression level of gastric cancer
cell lines (SGC7901, BGC823, MGC803, MKN28 and MKN45) compared with normal human gastric epithelial cell line (GES-1). (B) qRT-PCR analyses
of GAS5 expression level following treatment BGC823 and SGC7901 cells with pCDNA3.1-GAS5 or empty vector. (C) qRT-PCR analyses of GAS5
expression level following treatment MGC803 cells with si-GAS5 or si-NC. **P < 0.01.
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and B), while proliferation of MGC803 cells was in-
creased in si-GAS5 transfected cells compared with
respective controls (Figure 4A). Similarly, the results of
colony-formation assays revealed that clonogenic sur-
vival was decreased following upregulation of GAS5 in
pCDNA3.1-GAS5 transfected SGC7901 cells or BGC823
cells (Figure 3C and D), while enhanced in si-GAS5 trans-
fected MGC803 cells (Figure 4B).
To determine whether apoptosis was a contributing
factor to cell growth inhibition, we performed Hochest
staining analysis of pCDNA3.1-GAS5 transfected SGC7901
and BGC823 cells. The results showed that the number of
cells with condensed and fragmented nuclei indicating the
fraction of early apoptotic cells was significantly differentin SGC7901 and BGC823 cells with pCDNA3.1-GAS5
transfection compared with empty vector transfected cells
(Figure4C and D). In addition, we found that forced ex-
pression of GAS5 enhanced caspase-3-dependent apop-
tosis, demonstrated by western blot analysis of activated
caspase-3 after pCDNA3.1-GAS5 transfection (Figure 5A
and B). Taken together, these results indicate that upregu-
lation of GAS5 suppresses gastric cancer cell proliferation,
and induces cell apoptosis in vitro.
GAS5 inhibits gastric cancer cells tumorigenesis in vivo
To explore whether the level of GAS5 expression could
affect tumorigenesis, pCDNA3.1-GAS5 or empty vector
stably-transfected SGC7901 cells were inoculated into
female nude mice. Eighteen days after injection, the tumors
Figure 3 Ectopic expression of GAS5 inhibits gastric cancer cell proliferation in vitro. SGC7901 and BGC823 cells were transfected with
pCDNA3.1-GAS5 vector (or empty vector), respectively. (A) MTT assay was performed to determine the proliferation of pCDNA3.1-GAS5 transfected
SGC7901 and BGC823 cells. Data represent the mean ± s.d. from three independent experiments. (B) Viable cells were counted by trypan blue staining
at 72 h after transfection. (C, D) Colony-forming growth assay was performed to determine the proliferation of pCDNA3.1-GAS5 transfected SGC7901
and BGC823 cells. The colonies were counted and captured. **P < 0.01.
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smaller than those in the control group (Figure 6A and B).
Moreover, the mean tumor weight at the end of the ex-
periment was markedly lower in the pCDNA3.1-GAS5
group (0.21 ± 0.03 g) compared to the empty vector group
(0.67 ± 0.28 g) (Figure 6C). qRT-PCR analysis of GAS5
expression was then performed in selected tumor tissues.
The results showed that the levels of GAS5 expression in
tumor tissues formed from pCDNA3.1-GAS5 cells were
higher than those of tumors formed in control group
(Figure 6D). Immunostaining was used to analyze Ki67
protein expression in resected tumor tissues. Ki67 levels
in tumors formed from pCDNA3.1-GAS5 transfected
SGC7901 cells, exhibited decreased positivity for Ki67
than in tumors from control cells (Figure 6E). These re-
sults indicate that overexpression of GAS5 could inhibit
tumor growth in vivo.E2F1 and P21 are key downstream mediators of GAS5
Further exploration of the underlying mechanisms in-
volved in GAS5 overexpression induced growth arrest
was done by examining the expression of potential targets
after transfection with pCDNA3.1-GAS5 or empty vector.
The results showed that the expression of E2F1 was sig-
nificantly decreased and the expression of cyclin D1 wasalso downregulated in gastric cancer cells transfected with
pCDNA3.1-GAS5 compared to those with empty vector.
Moreover, increased P21 protein level were observed in
cells transfected with pCDNA3.1-GAS5 compared to
those with empty vector (Figure 5A and B). However, the
mRNA expression of E2F1, cyclinD1 or P21 remained
unaltered in the GAS5-overexpressed gastric cancer cells
compared with the vector controls (data not shown).
Meanwhile, we also assayed for changes in the protein
expression of E2F1, cyclinD1 and P21 in si-GAS5 trans-
fected MGC803 cells. As expected, when compared with
si-NC control cells, inhibition of GAS5 resulted in an
increase in E2F1 and cyclinD1 and a decrease of P21 levels
(Figure 5C). These data suggest that GAS5 maybe function
as an tumor suppressor by regulating E2F1 and P21
through post-transcriptional regulation, and further exper-
iments are needed to elucidate the potential mechanism.Discussion
LncRNAs dysregulation may affect epigenetic information
and provide a cellular growth advantage, resulting in pro-
gressive and uncontrolled tumor growth [14-18]. Effective
control of both cell survival and cell proliferation is critical
to the prevention of oncogenesis and to successful can-
cer therapy. Therefore, identification of cancer-associated
Figure 4 Downregulation of endogenous GAS5 promotes gastric cancer cell proliferation. (A) MTT assay was performed to determine the
proliferation of si-GAS5 transfected MGC803 cells. (B) Colony-forming growth assay was performed to determine the proliferation of si-GAS5 transfected
MGC803 cells. (C, D) The effect of GAS5 on gastric cancer cells apoptosis. SGC7901 and BGC823 cells were transfected with pCDNA3.1-GAS5
vector (or empty vector), respectively. Hoechst staining assay for cell apoptosis; the percentage of Hoechst-positive nuclei per optical field
(at least 50 fields) was counted. *P < 0.05.
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and functions may provide a missing piece of the well-
known oncogenic and tumor suppressor network puzzle.
GAS5 is a long ncRNA (~650 bases in humans) that
was originally isolated from a screen for potential tumor
suppressor genes expressed at high levels during growth
arrest [23]. Its encoding gene, gas5, comprises 12 exons
and encodes ten box C/D snoRNAs within its introns [24].
Two mature GAS5 lncRNAs, GAS5a and GAS5b, have also
been identified in humans due to the presence of alternative
5’-splice donor sites in exon 7, whereas GAS5b is the major
isoform (NR_002578.2, 77 nt, simply called GAS5 in this
study), and GAS5a has only 45 nt, missing 32 nt at the 3’
end [25]. GAS5 has been shown to be aberrantly expressed
in prostate cancer, renal cell carcinoma, breast cancer, headand neck squamous cell carcinoma (HNSCC), and glio-
blastoma multiforme [19-21,26]. For breast cancer and
HNSCC, low GAS5 expression is an adverse prognostic
factor for survival. Moreover, overexpression of GAS5
attributed to growth arrest of several cancer cell lines
through regulation of apoptosis and cell cycle, under
basal conditions or various cell death stimuli, including
chemotherapeutic agents, suggesting its clinical signifi-
cance in the development and therapy of cancer [19-21].
These data demonstrate the potential tumor-suppressor
role of GAS5; however, the relationship between expres-
sion of GAS5 and gastric cancer development and/or
progression remains unclear.
Our studies were designed to investigate the expression
and prognostic significance of GAS5 in patients with gastric
Figure 5 GAS5 affects E2F1 and P21 protein levels. (A, B)Western blot analysis of E2F1, CyclinD1, P21 and cleaved caspase-3 in pCDNA3.1-GAS5
transfected SGC7901 or BGC823 cells and respective control cells. (C) Western blot analysis of E2F1, CyclinD1 and P21 after si-GAS5 transfection with
MGC 803 cells. GAPDH protein was used as an internal control. * P < 0.05; ** P < 0.01.
Figure 6 Effects of GAS5 on tumor growth in vivo. (A, B) The tumor volume was calculated every three days after injection of SGC7901 cells
stably transfected with pCDNA3.1-GAS5 or empty vector. Points, mean (n = 3); bars indicate S.D. (C) Tumor weights were represented as means of
tumor weights ± s.d. (D) qRT-PCR analysis of GAS5 expression in tumor tissues formed from SGC7901/pCDNA3.1-GAS5, SGC7901/Empty vector.
(E). Tumors developed from pCDNA3.1-GAS5 transfected SGC7901 cells showed lower Ki67 protein levels than tumors developed by control cells.
Upper: H & E staining; Lower: immunostaining. * P < 0.05; ** P < 0.01.
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http://www.biomedcentral.com/1471-2407/14/319cancer. GAS5 expression was retrospectively analyzed in 89
patients with gastric carcinoma. Results were assessed for
association with clinical features and DFS/OS of gastric
cancer patients after gastrectomy. Prognostic values of
GAS5 expression and clinical outcomes were also evaluated
by Cox regression analysis. The results showed that GAS5
expression was significantly decreased in gastric cancer
tissues and cell lines. A lower expression of GAS5 was
detected in tumor of larger size, higher tumor stage,
deeper depth of invasion and more regional lymph nodes.
In addition, the downregulation expression of GAS5 was
associated with poor prognosis. Moreover, ectopic expres-
sion of GAS5 was demonstrated to decrease gastric cancer
cell proliferation and induce apoptosis, while downregula-
tion of endogenous GAS5 could promote cell proliferation
in vitro and in vivo. Taken together, these findings indicate
that GAS5 could function as a tumor suppressor via regu-
lating cell growth and apoptosis, and may be useful in the
development of novel prognostic or progression markers
for gastric cancer.
Although GAS5 has been suggested to have a tumor-
suppressive role, the underlying mechanism of GAS5-me-
diated gene expression having an impact on tumorigenesis
is still elusive. Kino et al. have found that GAS5 could
structurally mimic the glucocorticoid receptor response
element (GRE) to suppress GR-induced transcriptional
activity of endogenous glucocorticoid- responsive genes
[25]. Zhang et al. have provided a possible mechanism
for GAS5 as a tumor suppressor, which may be attributed
to its ability to suppress the oncogenic miR-21 in breast
cancer [27]. Nevertheless, since it’s highly possible that
target genes of lncRNAs differ between specific tissues
and cell types, specific target genes controlled by GAS5
for gastric pathogenesis remain unknown and deserve
investigation. In this study, to explore the molecular
mechanism by which GAS5 contributes to cell prolifera-
tion of gastric cancer, we investigated potential targets
which were responsible for cell cycle arrest and cell
growth inhibition. Our present experimental results
confirmed that E2F1, as well as Cyclin D1, were func-
tional targets of GAS5 in gastric cells. E2F1 expression
has been found to be upregulated in mutiple cancers,
and its overexpression contributes to many tumors de-
velopment by acting as an important transcript factor
regulating key regulator genes that controlling cell prolif-
eration [28,29]. Cyclin D1 is one of the most important
proteins to regulate cell cycle, and related with the devel-
opment of many cancers. Cyclin D1 binds and activates
CDK4/6, which subsequently phosphorylates tumor sup-
pressor protein Rb and allows the cell cycle to progress
through G1 into S [30]. Furthermore, P21 expression has
been shown to be reduced or lost in a variety of cancer
types [31]. A possible explanation is that P21 exerts its
inhibitory control over the cell cycle primarily throughdirect binding to cyclins and CDKs, therefore preventing
cell proliferation [32]. Here, we also found P21 was a
downstream regulator involved in GAS5-mediated growth
arrest in gastric cancer cells. Taken together, these findings
indicate that lncRNA GAS5 may function as a tumor sup-
pressor and its deficiency or decreased expression could
contribute to gastric cancer development; however, further
studies are required to clarify GAS5 regulation of the
above targets expression in gastric cancer cells.
Conclusion
In summary, we demonstrate that the decreased GAS5
expression is a common event underlying gastric cancer,
indicating that GAS5 may play a key tumor-suppressive
as an indicator of poor survival rate and a negative
prognostic factor for gastric cancer patients. Further
well understanding of the mechanisms of GAS5 in the
molecular etiology of gastric cancer will promote the
development of lncRNA-directed diagnostic and thera-
peutic agents against this deadly disease.
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